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Randomized, Placebo-Controlled, Double-Blind Study of
Ropinirole in Chronic Stroke
Steven C. Cramer, MD; Bruce H. Dobkin, MD; Elizabeth A. Noser, MD;
Rachelle W. Rodriguez; Lori A. Enney
Background and Purpose—Evidence suggests the potential to improve motor status in patients with stroke by modifying
brain catecholaminergic tone. The current study hypothesized that increased dopaminergic tone via the dopamine
agonist ropinirole, when combined with physiotherapy (PT), would significantly and safely increase gait velocity.
Methods—Patients with moderate motor deficits due to stroke 1 to 12 months prior were randomized (double blinded) to
9 weeks of immediate-release ropinirole or placebo, each with PT, and followed up for 3 additional weeks. Drug dose
(0.25 to 4 mg once daily) was titrated weekly, as tolerated. The primary end point was gait velocity during the 12 weeks
of study participation.
Results—Patients in the ropinirolePT group averaged 2.4 mg/d by end of week 9, although the target dose was at least
3 mg/d. RopinirolePT was generally safe and well tolerated, including no drug-related serious adverse events. Across
all 33 enrollees, significant gains were found over time for gait velocity and for most secondary end points. However,
gains did not differ by treatment assignment. PT and occupational therapy were commonly prescribed outside of the
trial, although the extent of these was not correlated with study outcomes.
Conclusions—At doses achieved in this trial, increased dopaminergic tone via ropinirolePT was generally well tolerated
but did not show any improvement over and above the effects of PT alone. (Stroke. 2009;40:3034-3038.)
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Stroke is a major source of disability. One approach toreducing poststroke disability is to maximize the function
of surviving brain elements, with suggested therapeutic tar-
gets in both the acute and chronic phases.1,2 One such
restorative approach is to modify tone within specific neuro-
chemical systems, particularly catecholaminergic systems.
Some,3,4 though not all,5,6 studies of drugs that broadly
increase activity within central nervous system (CNS) cate-
cholaminergic systems have suggested a favorable effect on
motor status after stroke. The precise CNS catecholamine
system affected by these studies is unclear because the
compounds evaluated have generally acted on multiple cate-
cholaminergic receptors.
The purpose of the current study was to extend these
prior observations of pharmacologic promotion of motor
system restoration after stroke by evaluating a drug that
acts on a single catecholaminergic system, dopamine.
Modulating brain dopaminergic tone was not intended to
replace a proposed poststroke dopamine deficit, as with
Parkinson disease, although focal changes in brain dopa-
minergic tone have been described after stroke.7–9 Instead,
the intent was to favorably affect processes that are known
to be dopamine responsive and that are also relevant to
behavioral recovery after stroke, such as mood, memory,
reward, motivation, attention, learning, movement, and
plasticity.10 –14 Each of these processes might be a means
by which increased dopaminergic tone after stroke might
improve CNS function.
The current study was a randomized, double-blind,
placebo-controlled trial to evaluate the effects of the DA2
dopaminergic agonist, immediate-release ropinirole, on gait
and related motor functions in patients in the early phase of
chronic stroke. The primary study hypothesis was that ropi-
nirole, when combined with physiotherapy (PT) during peak
serum drug levels, would result in greater gains compared
with placeboPT during the 12 weeks of study participation.
The primary end point was gait velocity, which is commonly
affected after stroke15 and is linked to outcomes and partici-
pation.16 Secondary end points were safety, gait endurance,
general leg motor function measured as the leg Fugl-Meyer
(FM) score, plus the aforementioned measures when exam-
ined during a shorter time interval (9 weeks).
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Subjects and Methods
Subjects and Study Overview
The main entry criteria were ischemic or hemorrhagic stroke 1 to 12
months prior to the study, age 18 to 80 years, prestroke modified
Rankin score 2, and motor deficits (arm/leg FM motor score 23 to
83 out of 100). Exclusion criteria included major depression; gait
difficulty that was either very mild (50-foot walk 15 seconds) or
severe (FM ambulation score 3) in magnitude; a substantial decrease
in alertness, language reception, or attention; pregnant or lactating;
advanced systemic medical disease; coexistent major neurologic or
psychiatric disease; orthostatic hypotension; concurrent use of drugs
known to interfere with the action of ropinirole; concurrent enroll-
ment in another stroke recovery investigation; or any contraindica-
tion to ropinirole. The choice of at least 1 month after stroke was
intended to ensure that acute stroke medical issues would have
reached resolution and also that enrollees would have completed
standard inpatient poststroke rehabilitation. The choice of no more
than 12 months after stroke was intended to minimize the variance
introduced by late poststroke changes, eg, contractures and psycho-
social decline.
After informed consent was obtained, eligibility was determined
and eligible subjects were randomized in a 1:1 fashion to either
immediate-release ropinirole or placebo in a double-blind manner.
Separate randomizations were used for subjects 3 months after
stroke (“early group”), and subjects 3 months after stroke (“late
group”); the 3-month cutoff was selected because many motor
behaviors reach a plateau at 3 months after stroke.17 Computer-
generated randomization schedules were generated for each site,
with envelopes connecting subject identification to treatment arm
assignment provided to each site’s unblinded pharmacist. Patients
received either drug or placebo for 9 weeks, with concomitant PT for
the last 4 of these weeks (Figure 1). Assessments were performed
weekly for 9 weeks. Final assessments were done at week 12, ie, 3
weeks after the end of drug therapy. Local institutional review
boards approved all procedures.
Therapeutic Intervention
In sum, drug dose was once daily and was titrated upward as
tolerated during the 9-week treatment period. For 4 weeks (the start
of week 6 to the end of week 9), a 90-minute standardized regimen
of PT was introduced, twice weekly, at peak drug levels, ie,1 hour
after ingestion.
Ropinirole is a medication that requires titrating. Thus, there were
9 visits at which drug tolerability/safety was assessed, the dose was
advanced as appropriate, and a new blister pack of pills was
dispensed. Each of these visits began with safety assessments that
consisted of review of concomitant medications, new symptoms, and
a check for orthostatic hypotension (drop of systolic or diastolic
blood pressure 15 mm Hg). For weeks 2 to 9, compliance was also
ascertained, with noncompliance defined as missing 3 of the 7
doses. After these assessments, the next week’s pill pack was
ordered.
For week 1, the pill was either placebo or ropinirole at the 0.25-mg
dose. Dosing was oral and daily throughout the study. For weeks 2
to 9, the dose was either the next highest dose according to the
schedule for dose advancement, if appropriate, or a lower dose,
based on the presence of any suspected drug-related side effects. The
subject was observed for 2 hours after ingesting the first pill at each
dose. The schedule for dose advancement was, for week 1, 0.25 mg;
week 2, 0.5 mg; week 3, 0.75 mg; week 4, 1 mg; week 5, 1.5 mg;
week 6, 2 mg; week 7, 2.5 mg; week 8, 3 mg; and week 9, 4 mg. Note
that the target was to have each patient reach at least 3 mg/d to
approximate the biologic effect achieved in a prior study of 100 mg/d
L-dopa.4 Although that prior study evaluated L-dopa, which must be
metabolized to become dopamine, and the current study evaluated
ropinirole, which is a DA2 dopaminergic agonist, the 2 have similar
biologic effects on brain dopaminergic tone. In all instances, the size,
color, weight, and number of pills to meet the ropinirole dose were
matched by the placebo pills.
For 4 weeks, from the start of week 6 to the end of week 9, PT was
introduced, twice weekly, for 90 minutes per session, standardized
across sites. Each PT session began 60 minutes after pill ingestion
and had 60 minutes focused on gait therapy and 30 minutes on arm
therapy. Subjects were discharged home with written instructions for
performance of home PT exercises, which prescribed at least 30
minutes/d of individually selected arm and leg exercises to be started
30 to 60 minutes after study pill ingestion.
Behavioral Testing
Baseline assessments included the Hamilton Depression Scale (17-
item version), Barthel Index, Stroke Impact Scale-16 (SIS-16), arm
and leg FM motor scales, gait velocity, and gait endurance. Gait
velocity was measured over a 50-foot (15.24 meters) hallway, with
the better of 2 efforts recorded. Gait endurance measured either the
distance walked up/down this hallway for 6 minutes or the distance
walked over time until the subject needed to stop (if 6 minutes).
Whenever possible, the same therapist performed all assessments for
a given patient over time.
Gait velocity, gait endurance, and FM scores were reassessed 7
more times to week 12; SIS-16, 4 more times; and the Barthel Index
and the Hamilton Depression Scale, 2 more times. Gait studies and
FM scoring were performed 30 to 60 minutes after study drug
ingestion. At the end of week 12, each subject was asked to guess which
treatment group he/she was randomized to, and the results were
recorded. At all visits, adverse events, amount of therapy received
outside the study, and concomitant medications were reviewed.
Statistics
Statistical analyses included 2-tailed parametric methods. Continu-
ous variables were compared by ANOVA testing; categorical vari-
ables, by Fisher’s exact test. Missing data were imputed by carrying
the last measured value forward.
Initial power estimates, adapted from Sullivan et al,18 anticipated
a baseline gait velocity of 0.350.6 m/s (meanSD) and end-of-
treatment gait velocities of 0.49 m/s for subjects in the
ropinirolePT group versus 0.41 m/s for those in the placeboPT
group. This suggested that 26 patients were required in each study
arm to achieve 80% power at 0.05. Preliminary analysis of
blinded data from 24 patients disclosed mean baseline gait velocities
of 0.550.31 m/s at baseline and 0.710.39 m/s across the 2 groups
at the end of study drug administration, leading to a revised sample
size estimate of 17 patients in each study arm.
Results
Subjects
A total of 744 patients were screened from February 2004 to
February 2007, of whom 33 patients were enrolled: 25 from
the University of California Irvine, 4 from UCLA, and 4 from
the University of Texas at Houston. The most common
reasons for screening failure were that the patient was too
strong (211), spoke no English (86), was too weak (82), was
1 year after stroke (65), declined participation (45), or had
psychiatric comorbidity, including dementia (35).
Of the 33 enrolled, 7 were3 months after stroke (“early”;
3 randomized to placeboPT and 4 to ropinirolePT), and
Figure 1. Time course of the study. After completing baseline
studies, subjects received 9 weeks of daily study medication,
either ropinirole or placebo, with weekly safety visits during
these 9 weeks. Beginning at week 6, 4 weeks of twice-weekly
PT began. After a 3-week washout period, the final examination
was administered. Triangles indicate times when gait velocity,
the primary end point, was measured.
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26 were 3 months after stroke (“late”; 13 subjects in each
group). Overall, at baseline, subjects were well matched
across the 2 treatment groups, although a significant excess of
diabetes was present in the ropinirolePT group (Table 1).
The distribution of stroke subtypes did not differ between
treatment groups (P0.9). Rankin Scale scores at baseline
did not differ between groups, being 0 to 1 in all but 1 subject.
Study Therapy and Safety
Medication dose was advanced according to the schedule more
often in the placeboPT group than in the ropinirolePT group.
Thus, in the placeboPT group, the peak dose averaged
3.60.9 mg, and 13 patients reached the 4-mg/d dose at week 9;
note that this was a virtual dose, because no active drug was
actually given to subjects in the placeboPT group. How-
ever, in the ropinirolePT group, the peak daily dose
averaged 2.41.2 mg, and only 4 patients reaching the
4-mg/d dose at week 9. Medication compliance was high,
because only 3 patients (2 in the ropinirolePT group and 1
in the placeboPT group) had a week of noncompliance.
Overall, ropinirolePT was generally safe and well toler-
ated. Five serious adverse events occurred, none of which
was attributed to ropinirolePT. One of these, falling, was
deemed possibly or probably related to study medication by
blinded study personnel; this patient was later learned to be in
the placeboPT group. The other 4 serious adverse events
(new ischemic stroke, urinary tract infection, facial sensori-
motor symptoms, and death from bile duct cancer) were each
thought by blinded study personnel to be unrelated to the
study medication. These 4 patients were all in the
ropinirolePT group. Nonserious adverse events present in at
least 5 patients and deemed possibly or probably related to
the study medication by blinded study personnel included
sleepiness (8/1), fatigue (6/0), and dizziness (3/2) (No. in the
ropinirolePT group/No. in the placeboPT group).
Outside Therapy
Therapy prescribed by the enrollee’s caregivers during study
enrollment, and thus outside of study activities, was allowed
by the protocol and was common (Table 2). PT was admin-
istered most often; occupational therapy, most intensively (ie,
highest number of sessions). Subjects in the placeboPT
group were significantly more likely to receive PT.
Behavioral Effects
Across all subjects, significant gains in gait velocity were seen
from baseline to week 12, being 0.220.21 m/s, ie, 42%, higher
than at baseline (repeated-measures ANOVA, P0.0001).
Gains were also significant to week 9 (P0.0001). Significant
gains were also seen at both time points for gait endurance, leg
FM score, and SIS-16 score. Changes in arm FM score and
Barthel Index were not significant at either time point.
Interestingly, from baseline to week 4, before any PT,
significant gains were seen for gait velocity, gait endurance,
and SIS-16 score. Note that these gains from baseline to week
4 were smaller in patients with more chronic stroke, such that
the extent of gains was inversely related to the number of
days after stroke at the time of study enrollment for gait
velocity (P0.05) and for gait endurance (P0.06).
No differences between treatment groups were apparent at
the end of either treatment or study, however, because the
timegroup interaction term (repeated-measures ANOVA)
was not significant at either time point for gait velocity
(Figure 2), gait endurance, leg FM score, SIS-16 score, arm
FM score, or Barthel Index. The lack of difference between
treatment groups remained true when only subjects in the
“early” group were evaluated and when only subjects in the
“late” group were evaluated. In addition, no significance was
present when gait velocity, gait endurance, and leg FM score
Table 1. Baseline Assessments
RopinirolePT
(n17)
PlaceboPT
(n16) P
Age, y 6313 6015 0.47
Sex, M/F 11/6 12/4 0.71
Time after stroke, d 19297 233110 0.26
Index stroke was first stroke 14 12 1.0
Smoking history, 10 pack-y 3 2 1.0
Previously diagnosed with
Hypertension 11 10 1.0
Hyperlipidemia 12 12 0.69
Diabetes mellitus 5 0 0.046
Atrial fibrillation 0 0 1.0
Coronary artery disease 3 1 0.60
Baseline value for
Gait velocity, m/s 0.540.37 0.490.28 0.67
Leg FM score 215 236 0.38
Arm FM score 3217 2617 0.34
Gait endurance
(m over 6 min)
140103 13482 0.86
Hamilton depression score 74 43 0.048
FIM ambulation score 5.21.3 5.41.1 0.57
Barthel Index 8120 8016 0.85
SIS-16 5610 5811 0.65
Normal FM scores are 66 for the arm, 34 for the leg. Values are meanSD
or numbers of subjects, as appropriate.
Table 2. Therapy Received by Patients Outside of the Study
Type of Therapy
No. of Subjects Receiving Any Outside
Therapy During Study Participation in
the RopinirolePT Group (n17)
No. of Subjects Receiving Any Outside
Therapy During Study Participation in
the PlaceboPT Group (n16) P
Mean No.
of Sessions
Occupational therapy 4 4 1.0 21
Physical therapy 7 13 0.03 12
Speech therapy 4 1 0.34 19
Mean No. of sessions is the mean among both groups for those patients who did receive outside therapy.
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were further examined by adding terms for either time after
stroke or the total number of all outside therapy sessions.
Furthermore, neither total number of all outside therapy
sessions nor total number of PT sessions was correlated with
a change in any primary or secondary end point to week 9 or
12. Note that repeated-measures ANOVA found significant
(P0.03) gains in gait velocity during the 12 weeks when we
examined the subjects in the ropinirolePT group only and
when we examining the subjects in the placeboPT group
only.
Medication Effects and Blinding
Medication effects overcame blinding in the ropinirolePT
group in nearly all cases. Among the 14 patients randomized
to ropinirolePT who ventured a guess at week 12 as to
treatment assignment, 13 of 14 (93%) guessed correctly. In
the placeboPT group, guesses were at chance level, as 8 of
15 (53%) guessed correctly, a proportion of correct guesses
that is significantly (P0.02) lower compared with that in the
ropinirolePT group.
Discussion
Several lines of evidence suggest that increased CNS dopa-
minergic tone might be useful for restoring function after
stroke, given the key role this neurotransmitter has on mood,
memory, reward, motivation, attention, learning, movement,
and plasticity.10–14 This study aimed to evaluate safety and
gait/motor effects of ropinirolePT in patients with chronic
stroke. RopinirolePT was safe and well tolerated. Across all
subjects, significant gains were found for gait velocity and
other motor measures, but there was no difference between
the 2 treatment arms.
The main study hypothesis was that ropinirolePT was
superior to placeboPT for increasing gait velocity, but the
data did not support this. There are several possible interpre-
tations. First, the findings might in part reflect baseline
imbalances, with higher diabetes prevalence and depression
(Table 1) and less outside PT (Table 2) possibly reducing the
extent of gait improvement in the ropinirolePT group.
Second, the findings might indicate that increased dopami-
nergic tone simply does not improve motor function after
stroke, a view supported by some19,20 but not other21,22
preclinical studies. Furthermore in this regard, some of the
heterogeneity in ropinirole effects might stem from the fact
that dopaminergic influences vary according to basal dopa-
mine level,23 and these levels might vary in relation to
features of stroke injury, a possible consideration for future
trials. Third, the intensity and duration of PT were modest,
which might have limited the ability to detect a difference in
treatment groups.24 Fourth, subjects in the ropinirolePT
group were able to guess treatment assignment in all but 1
case, whereas subjects in the placeboPT group guessed at
chance, possibly indicating the presence of an expectation
bias. Fifth, variability in time after stroke at study entry might
indicate the coexistence of several biologically distinct pa-
tient subgroups.
An additional interpretation of the current results is that the
study hypothesis was not fully investigated. Patients in the
ropinirolePT group reached an average daily dose of
2.41.2 mg by week 9, indeed spending most of the 9 weeks
at a dose lower than this, all lower than the 3-mg/d target.
Whether higher doses of ropinirole would be superior to
placebo in improving motor function after stroke remains to
be determined. For the aforementioned reasons and because
this study enrolled a small number of patients with mixed
stroke subtypes, the current report must not be considered
conclusive, instead indicating a need for further investigation
of the effects of modulating dopaminergic tone after stroke.
Some observations might be of value to future trials of
restorative therapies targeting patients with stroke. Gait
velocity and other measures were significantly improved by
study week 4, ie, before initiation of PT in either group and
at a time when the dose of ropinirole was still very low. This
finding might reflect incomplete spontaneous recovery in
some patients at the time of study entry (supported by the
inverse relation between time after stroke and gains to week
4), overcoming of learned disuse, effects of repeated testing,
or direct psychosocial effects of study participation.25 Sec-
ond, outside therapy was common among subjects in both
treatment arms. Although the amount of such therapy had
little relation to outcomes in the current study, experience is
nonetheless important in shaping outcome after stroke and in
enabling restorative therapies,26 and might therefore be im-
portant in other studies. Furthermore, poststroke rehabilita-
tion is highly variable in some countries and difficult to
control in others, providing an additional reason to measure
its extent in a clinical trial context.
Across all patients in this study, significant improvements
in gait velocity and other motor assessments were found over
time. At doses achieved in this trial, ropinirolePT was
generally safe and well tolerated; however, this combination
did not show any improvement over and above the effects of
placeboPT. PT was commonly prescribed outside of study
activities and so represents a potential confounder in restor-
ative trials.
Figure 2. Main study result. Across all subjects, gait velocity
improved significantly over time, from baseline to week 4, to
week 9, and to week 12. However, there were no significant dif-
ferences according to treatment group for any of these time
intervals.
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